Simvastatin therapy in patients with hepatic disease
Aim. To assess effectiveness, safety, and tolerability of simvastatin (Vasilip) in patients with IIa and IIb dyslipidemia, as well as with hepatic disease. Material and methods. The analysis included 30 patients receiving Vasilip (20 mg/d). At baseline and after 3, 6, and 14 months of the treatment,...
Saved in:
| Main Authors: | O. M. Drapkina, A. V. Klimenkov, I. I. Sukhovskaya, V. T. Ivashkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2007-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving Cofactor Promiscuity of HMG-CoA Reductase from <i>Ruegeria pomeroyi</i> Through Rational Design
by: Haizhao Xue, et al.
Published: (2025-07-01) -
Virtual screening and evaluation of bioactive peptides from Haliotis discus hannai as potential HMGCR inhibitors for hyperlipidemia treatment
by: Kun Qiao, et al.
Published: (2024-12-01) -
Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy
by: Małgorzata Ostrowska, et al.
Published: (2015-12-01) -
Effect of selenium on main active component contents of Ganoderma lingzhi in different periods
by: YE Liyun, et al.
Published: (2017-07-01) -
Immune-mediated necrotizing myositis with hydroxy-3-methyl-glutaryl-coenzyme A reductase antibody positivity in MSA-negative and statin-naive profile
by: Kothapalli Nagamounika, et al.
Published: (2023-01-01)